efanesoctocog alfa (BIVV001) for hemophilia a

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Nov 2020: Trial registered, NCT04644575
  2. 23 Feb 2021: Trial started, NCT04644575

The trials

NCT04644575: Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

State
Under way
Phase
Phase 3
People
261 taking part
Started
23 Feb 2021
Primary completion
15 Jan 2027
Arms
Arm A: Previously treated in BIVV001 study, Arm B: Newly initiated (China Only) in BIVV001, Arm C: Newly initiated in BIVV001 with planned major surgery
Results
None posted
  1. 25 Nov 2020: Trial registered
  2. 23 Feb 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.